Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Repurchased Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Growth Metrics

United Health Products (UEEC) Capital Expenditures (2020)

United Health Products' Capital Expenditures history spans 1 years, with the latest figure at $9261.0 for Q4 2020.

Quarterly results put Capital Expenditures at $9261.0 for Q4 2020, changed N/A from a year ago — trailing twelve months through Dec 2021 was $14350.0 (changed 0.0% YoY), and the annual figure for FY2020 was $101350.0, changed.
Capital Expenditures for Q4 2020 was $9261.0 at United Health Products, up from $5089.0 in the prior quarter.
In the past five years, Capital Expenditures ranged from a high of $9261.0 in Q4 2020 to a low of $5089.0 in Q3 2020.